Mark served as Head of Plasma Proteins at Therapure Biopharma Inc. from 2011 until the formation of Evolve Biologics and has been in the pharmaceutical industry for over 15 years He previously held progressively senior positions within the finance operations at Valeant (formerly Biovail). As Director, Financial Analysis and Planning, Mark worked closely with business development, R&D, and manufacturing, particularly during licensing transactions. Mark earned both a BSc in biology from the University of British Columbia and an MBA from Richard Ivey School of Business and is a Certified Professional Accountant.